CANCER AND LEUKEMIA GROUP B

描述（改编自申请人的摘要）：北京大学

DESCRIPTION (adapted from the applicant's abstract): The University of Chicago has had a major commitment to both laboratory and clinical cancer research since 1930. As part of the clinical translation of that research, the University of Chicago and its Cancer Research Center joined the Cancer and Leukemia Group B (CALGB) in 1985, and has subsequently strongly supported the CALGB both scientifically and clinically. Numerous protocols, committees, and programs are lead by Chicago faculty. Over the past five years the University of Chicago has increased its accrual from 184 patient points to 294 patient points, and in 1996 27 percent of the main member's patient accrual was African American. These accomplishments occurred by disciplined activity at the main member and also by supporting seven dedicated affiliated institutions in northern Illinois, Michigan and Indiana. Chicago is in the process of adding three new affiliates in the next year and remains very involved with the training and quality control of all its affiliate institutions. The goals of this application are: (1) increase the patient accrual to 300-350 patients/year; (2) to lead and assist CALGB scientific activities in the disease-related committees of respiratory (Drs. Vokes and Olak), prostate (Drs. Vogelzang, Steinberg and Vijaykumar), breast (Dr. Fleming), leukemia (Dr. Larson) and GI (Dr. Mani); (3) to lead and assist and participate in the CALGB committees such as psycho/oncology (Marcy List, Ph.D.), pharmacology and experimental therapeutics (Dr. Ratain), transplantation (Dr. Williams), genetics (Dr. Olopade), AIDS related malignancies (Dr. Liebowitz), surgical oncology (Dr. Michelassi) and pathology (Dr. Vardiman); (4) to encourage Chicago faculty to be protocol chairs for future protocols; and (5) to actively assist and participate in the CALGB committees of audit, minority issues, oncology nursing, cancer control, and radiotherapy. The University of Chicago proposes to accomplish these goals by the following methods: (1) to increase accrual from the main member with the assistance of new energetic physicians in colorectal, breast, surgery, leukemia and prostate cancer and by generating new ideas for phase I, II and III protocols; (2) to maintain the high accrual from the affiliate hospitals and increasing accrual by adding new qualified affiliates; (3) to maintain the strong leadership roles of Drs. Vogelzang, Vokes, Larson, Schilsky, Ratain, Williams, Olopade, List, Vardiman and Michelassi within the CALGB; (4) to recruit new young investigators to CALGB leadership roles (Drs. Manni, Leibowitz and Daugherty); especially those with a specific laboratory expertise which can be correlated with clinical treatment or outcome; and (5) to provide volunteers for numerous CALGB administrative committees. The University of Chicago and its affiliates remain firmly committed to serving all members of their respective communities, especially serving the needs of women and minorities.